Traded Nov 18, 2025 · Filed Nov 19, 2025
A big owner of Eli Lilly sold $8.36M of Eli Lilly shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$8,362,059
Shares × reported transaction price
19 days after results of Oct 30, 2025, 78 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1,030.05 on Nov 18, 2025, at its 52-week high, after a 22% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $1,030.05 (Nov 18, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $843.63 on Oct 7, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Retevmo on Nov 20, 2025, 2 days after this trade.
New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.1% | +4.7% | −1.6% |
| 30 days | +3.2% | +5.0% | −1.8% |
| 90 days | −2.2% | +5.2% | −7.3% |
| 180 days | −2.1% | +12.4% | −14.5% |
Past results only. Not a forecast.
David J. Taylor soldRepublican, Representative, OH district 29 different filers disclosed LLY within 90 days. Disclosed 9 days after the transaction; reported as an official range, not an exact amount.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
